ArticleRheumatology international2025
Increased retinal thickness in sarcoidosis patients with ocular system involvement visualized with optical coherence tomography: a cross-sectional study.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ocular Sarcoidosis: Contemporary Insights and Future Directions.Romanian journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the thickness of retinal structures in patients with neurosarcoidosis (NS) and ocular sarcoidosis (OS). We compared the central macular thickness (CMT), retinal thickness (RT), central nerve fiber layer (RNFL) thickness, and ganglion cell layer (GCL) thickness using optical coherence tomography. In a cross-sectional study, we categorized 97 sarcoidosis patients (185 eyes) into four groups: patients without ocular or central nervous system sarcoidosis (Non-Ocular/Non-CNS, n = 53), patients with OS (Ocular, n = 13), patients with NS (CNS, n = 16), and patients with combined OS and NS (Ocular/CNS, n = 15). The mean age was 51 (14) years. We found no overall difference between the groups in the CMT (p = 0.3), RT (p = 0.9), RNFL (p = 0.3), and GCL measurements (p = 0.9). Only in patients with a disease duration of more than five years, the CMT was significantly thicker in the Ocular group (278 μm, p < 0.001), the CNS group (267 μm, p = 0.04), and the Ocular/CNS group (268 μm, p = 0.04), compared to the Non-Ocular/Non-CNS group (249 μm). The RT was significantly thicker in the Ocular group (296 μm, p = 0.008) and the Ocular/CNS group (291 μm, p = 0.03) compared to the Non-Ocular/Non-CNS group (283 μm). In the RNFL measurements, the Ocular group (33.7 μm, p = 0.002) was thicker than the Non-ocular/Non-CNS group (29.1 μm). We found an increased retinal thickness in patients with ocular sarcoidosis and long disease duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.